NAVAMEDIC (NAVA.OL) Fundamental Analysis & Valuation

OSL:NAVA • NO0010205966

Current stock price

19.7 NOK
+0.05 (+0.25%)
Last:

This NAVA.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. NAVA.OL Profitability Analysis

1.1 Basic Checks

  • In the past year NAVA has reported negative net income.
  • The reported net income has been mixed in the past 5 years: NAVA reported negative net income in multiple years.
  • The reported operating cash flow has been mixed in the past 5 years: NAVA reported negative operating cash flow in multiple years.
NAVA.OL Yearly Net Income VS EBIT VS OCF VS FCFNAVA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -3.17%, NAVA is doing worse than 64.71% of the companies in the same industry.
  • NAVA has a Return On Equity of -7.05%. This is in the lower half of the industry: NAVA underperforms 64.71% of its industry peers.
  • NAVA has a worse Return On Invested Capital (1.69%) than 62.75% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for NAVA is significantly below the industry average of 14.61%.
  • The last Return On Invested Capital (1.69%) for NAVA is well below the 3 year average (6.26%), which needs to be investigated, but indicates that NAVA had better years and this may not be a problem.
Industry RankSector Rank
ROA -3.17%
ROE -7.05%
ROIC 1.69%
ROA(3y)-2.35%
ROA(5y)0.17%
ROE(3y)-5.41%
ROE(5y)-0.36%
ROIC(3y)6.26%
ROIC(5y)7.33%
NAVA.OL Yearly ROA, ROE, ROICNAVA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20 30

1.3 Margins

  • NAVA's Operating Margin of 2.19% is on the low side compared to the rest of the industry. NAVA is outperformed by 62.75% of its industry peers.
  • In the last couple of years the Operating Margin of NAVA has declined.
  • The Gross Margin of NAVA (38.97%) is worse than 76.47% of its industry peers.
  • NAVA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 2.19%
PM (TTM) N/A
GM 38.97%
OM growth 3Y-42.65%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y3.08%
NAVA.OL Yearly Profit, Operating, Gross MarginsNAVA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. NAVA.OL Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NAVA is destroying value.
  • The number of shares outstanding for NAVA has been increased compared to 1 year ago.
  • Compared to 5 years ago, NAVA has more shares outstanding
  • The debt/assets ratio for NAVA is higher compared to a year ago.
NAVA.OL Yearly Shares OutstandingNAVA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
NAVA.OL Yearly Total Debt VS Total AssetsNAVA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • NAVA has a Debt/Equity ratio of 0.52. This is a neutral value indicating NAVA is somewhat dependend on debt financing.
  • NAVA's Debt to Equity ratio of 0.52 is in line compared to the rest of the industry. NAVA outperforms 54.90% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Altman-Z N/A
ROIC/WACC0.2
WACC8.5%
NAVA.OL Yearly LT Debt VS Equity VS FCFNAVA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • NAVA has a Current Ratio of 1.55. This is a normal value and indicates that NAVA is financially healthy and should not expect problems in meeting its short term obligations.
  • NAVA has a better Current ratio (1.55) than 62.75% of its industry peers.
  • A Quick Ratio of 0.89 indicates that NAVA may have some problems paying its short term obligations.
  • NAVA's Quick ratio of 0.89 is on the low side compared to the rest of the industry. NAVA is outperformed by 60.78% of its industry peers.
Industry RankSector Rank
Current Ratio 1.55
Quick Ratio 0.89
NAVA.OL Yearly Current Assets VS Current LiabilitesNAVA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NAVA.OL Growth Analysis

3.1 Past

  • NAVA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -214.60%.
  • NAVA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.38%.
  • NAVA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 21.92% yearly.
EPS 1Y (TTM)-214.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.48%
Revenue 1Y (TTM)6.38%
Revenue growth 3Y13.95%
Revenue growth 5Y21.92%
Sales Q2Q%19.77%

3.2 Future

  • The Earnings Per Share is expected to grow by 57.68% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, NAVA will show a quite strong growth in Revenue. The Revenue will grow by 15.44% on average per year.
EPS Next Y31.75%
EPS Next 2Y60.85%
EPS Next 3Y57.68%
EPS Next 5YN/A
Revenue Next Year21.15%
Revenue Next 2Y19%
Revenue Next 3Y17.67%
Revenue Next 5Y15.44%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
NAVA.OL Yearly Revenue VS EstimatesNAVA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B
NAVA.OL Yearly EPS VS EstimatesNAVA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. NAVA.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NAVA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NAVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NAVA.OL Price Earnings VS Forward Price EarningsNAVA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NAVA.OL Per share dataNAVA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

  • NAVA's earnings are expected to grow with 57.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.85%
EPS Next 3Y57.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NAVA.OL Dividend Analysis

5.1 Amount

  • No dividends for NAVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NAVA.OL Fundamentals: All Metrics, Ratios and Statistics

NAVAMEDIC

OSL:NAVA (3/25/2026, 1:50:38 PM)

19.7

+0.05 (+0.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-30
Earnings (Next)N/A
Inst Owners30.98%
Inst Owner ChangeN/A
Ins Owners12.02%
Ins Owner ChangeN/A
Market Cap472.41M
Revenue(TTM)565.36M
Net Income(TTM)-23.54M
Analysts82.86
Price Target36.72 (86.4%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.39%
Min Revenue beat(2)-5.89%
Max Revenue beat(2)-4.89%
Revenue beat(4)0
Avg Revenue beat(4)-5.81%
Min Revenue beat(4)-7.18%
Max Revenue beat(4)-4.89%
Revenue beat(8)1
Avg Revenue beat(8)-6.13%
Revenue beat(12)3
Avg Revenue beat(12)-2.57%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-159.72%
EPS NY rev (3m)-159.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.71%
Revenue NY rev (3m)-5.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.84
P/FCF N/A
P/OCF N/A
P/B 1.41
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS23.58
BVpS13.93
TBVpS-5.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -3.17%
ROE -7.05%
ROCE 2.19%
ROIC 1.69%
ROICexc 1.98%
ROICexgc 38.65%
OM 2.19%
PM (TTM) N/A
GM 38.97%
FCFM N/A
ROA(3y)-2.35%
ROA(5y)0.17%
ROE(3y)-5.41%
ROE(5y)-0.36%
ROIC(3y)6.26%
ROIC(5y)7.33%
ROICexc(3y)7.3%
ROICexc(5y)9.2%
ROICexgc(3y)92.68%
ROICexgc(5y)70.31%
ROCE(3y)8.13%
ROCE(5y)9.52%
ROICexgc growth 3Y-12.15%
ROICexgc growth 5YN/A
ROICexc growth 3Y-52.01%
ROICexc growth 5YN/A
OM growth 3Y-42.65%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.07%
GM growth 5Y3.08%
F-ScoreN/A
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.55
Quick Ratio 0.89
Altman-Z N/A
F-ScoreN/A
WACC8.5%
ROIC/WACC0.2
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-214.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.48%
EPS Next Y31.75%
EPS Next 2Y60.85%
EPS Next 3Y57.68%
EPS Next 5YN/A
Revenue 1Y (TTM)6.38%
Revenue growth 3Y13.95%
Revenue growth 5Y21.92%
Sales Q2Q%19.77%
Revenue Next Year21.15%
Revenue Next 2Y19%
Revenue Next 3Y17.67%
Revenue Next 5Y15.44%
EBIT growth 1Y-68.56%
EBIT growth 3Y-34.65%
EBIT growth 5YN/A
EBIT Next Year288.89%
EBIT Next 3Y90.28%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

NAVAMEDIC / NAVA.OL Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for NAVAMEDIC?

ChartMill assigns a fundamental rating of 2 / 10 to NAVA.OL.


Can you provide the valuation status for NAVAMEDIC?

ChartMill assigns a valuation rating of 1 / 10 to NAVAMEDIC (NAVA.OL). This can be considered as Overvalued.


What is the profitability of NAVA stock?

NAVAMEDIC (NAVA.OL) has a profitability rating of 2 / 10.